Pneumonia Diagnostics & Technologies Market – Evaluating New Diagnostic Technologies

Pneumonia is a type of lung infection caused by microorganisms such as bacteria, virus, fungi and parasites. Streptococcus pneumonia is one of the most common causes of pneumonia among children, others are Haemophilus influenzae type b (Hob) and Pneumocystis jiroveci. It is characterized by symptoms such as short breathing, fever, chest pain, nausea and vomiting. In pneumonia the air sacs of lungs called as alveoli are filled with fluid or pus that causes inflammation. The treatment of pneumonia depends on severity of symptom and types of pathogens. Usually, antibiotics are given to treat pneumonia caused by bacterial infection while to treat pneumonia caused by fungi, antifungals are prescribed.

Current Industrial Trends of Pneumonia Diagnostics & Technologies: http://bit.ly/2eErhX2

It is quite difficult to diagnose pneumonia as its clinical symptoms overlap with many other diseases such as the asthama, bronchitis and common cold. In order to confirm pneumonia, a doctor recommends tests including chest X-ray, blood tests, sputum test, CT scan, pleural fluid culture and pulse oximetry test. The market for pneumonia diagnostics and technologies can be estimated on the basis of volume of tests generated at hospitals, diagnostic laboratories, physician’s own clinics and other healthcare settings. Chest x-ray and CT scan are generally recommended at hospitals for the diagnosis of pneumonia while community healthcare settings usually recommend diagnosis on the basis of symptoms. Some of the key players operating in this market space are Becton Dickinson, Affymetrix, Bio-Rad, Abbott Laboratories, Roche, Thermo Fisher Scientific, bioMeriux, DiaSorin and Novartis Diagnostics. Some of the diagnostic kits available in the market are Directigen S. pneumonia test kit by Becton Dickinson and LCx Chlamydia pneumonia PCR assay kit by Abbott Laboratories.

Read the Market Growth of Pneumonia Diagnostics & Technologies at: http://www.transparencymarketresearch.com/pneumonia-diagnostics-technologies.html

The market for pneumonia diagnostics and technologies is projected to grow under the influence of increasing aging population, recent advances in pneumonia diagnostics and high prevalence of pneumonia among children. Rapid increase in aging population in North America, Europe and Japan will be driving the market in these regions as elder people are more susceptible to develop pneumonia compared to general population. As of April 2013, WHO (world health organization) suggests that pneumonia is one of the major factors causing death in children. It is estimated that every year approximately 1.2 million children under the age of five years die due to pneumonia. This disease is most prevalent in South Asia and African countries. The recent advancement in pneumonia diagnostics such as the development of nucleic acid detection tests for major pneumonia pathogens and immunochromatographic pneumococcal urinary antigen tests are predicted to drive the market globally.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.